Skip To Main Content
Yueyin Pan on Muck Rack

Yueyin Pan

As seen in: Nature, The BMJ, JAMA (The Journal of the American Medical Association), JAMA Oncology, JAMA: Journal of the American Medical Association, The Lancet, Lung Cancer
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yueyin

Contact Yueyin, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study

|
By Jia Yu, Anwen Xiong, Qiming Wang, Jianhua Chen, Chengzhi Zhou, Panwen Tian, Wu Zhuang, Jie Li, Jing L. Wang, Junguo Lu, Kangsheng Gu, Jinsheng Shi, Jun Guo, Yonghui Di, Dongqing Lv, Debin Sun, Liming Cao, Zhixiong Yang, Jingxun Wu, Liyun Miao, Yueyin Pan, Chong Li, Xiaohong Wu, Jie Yin, Xiang Wang, Meili Sun, Miao He, Shundong Cang, Haohui Fang, Ping Chen, Min Zhang, Xinmei Yang, Hui Zhao, Jian Feng, Xuezhen Ma, Sheng Hu, Jian Lu, Xin Zhao, Zhixiang Zhuang, Yilan Sun, Xu Sun, Bing Yu, Chaonan Zhu, Jianghua Chen, June Xu, Kai Wang, Caicun Zhou, Hongrui Niu
| Nature Verified
Abstract Mefatinib, a novel second-generation epidermal growth factor (EGFR) tyrosine kinase inhibitor that has shown promising antitumor activity in targeting non-small cell lung cancer (NSCLC) with common and uncommon EGFR-activating mutations.
Open in Who Shared Issue with article?

First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer : Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial

|
By Jingjing Liu, Lin Wu, Jun Chen, Hongmei Sun, Guilan Wen, Yinghua Ji, Jianhua Shi, Zhijie Pan, Jinsheng Shi, Xicheng Wang, Yuansong Bai, Yueyin Pan, Xuhong Min, Maksym Viguro, Xingya Li, Yanqiu Zhao, Junquan Yang, Tamta Makharadze, Ekaterine Arkania, HAOYU YU, Jing Li, Xinyi Yang, Qingyu Wang, Jun Zhu, Ahmet Bilici, Aihong Zhong, Alexandre Tavartkiladze, Bangwei Cao, Chun Liang Chen, Davit Giorgadze, Denys Pominchuk, Devrim Cabuk, Dongji Chen, Fedor Moiseenko, Feng Luo, Gaofeng Li, Gongyan Chen, Guangyu An, Guoping Sun, Guosheng Feng, Yanrong Song, Haixin Huang, Hakan Harputluoglu, Hao Xiong, Hui Zhao, Igor Bondarenko, Irfan Cicin, Ivan Sinelnikov, Jian Fang, Jiuwei Cui, Junguo Lu, Kejing Ying, Konstantin Penkov, Liqin Lu, Liyan Jiang, Lu Yue, Mahmut Gümüş, Mehmet Artaç, Mengzhao Wang, Min Fan, Mustafa Özgüroğlu, Peiguo Cao, Peiyan Zhao, Ping Sun, Robert M. Mróz, Sergey Orlov, Shuang Zhang, Shuqun Zhang, Tao Zhang, Tuncay Göksel, Wen Lin, Wenlei Zhuo, Xiaoli Zhu, Xiubao Ren, Yan Wang, Yanping Hu, Yarong Li, Ying Cheng, Yuksel Urun, Zhendong Chen, Zhenyu You, Zhixiong Yang, Zhong Lin, Zhuang Yu, Alev Türker, Amiran Matitashvili, Andrey Akopov, Andrii Gardashnikov, Cagatay Arslan, Eugeny Kulikov, Igor Lifirenko, Ligong Nie, Malgorzata Ulanska, Maria Smagina, Mariam Zhvania, Nadezhda Kovalenko, Oleg Kobziev, Oleksii Kolesnik, Olexandr Goloborodko, Sergey Cheporov, Shenpeng Ying, Tariel Kitiashvili, Timur Andabekov, Tsira Kortua, Vadim Shirinkin, Vladimer Kuchava, Yevhen Hotko, Yuriy Semegen
| JAMA Oncology Verified
First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer: Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial Key Points Question What are the long-term efficacy and safety outcomes of adding serplulimab to first-line chemotherapy for previously untreated extensive-stage small cell lung cancer (ES-SCLC)?
Open in Who Shared Issue with article?

Savolitinib in MET -amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial

|
By Zhi Peng, Tianshu Liu, Hua Wang, Jufeng Wang, Hongli Liu, Feng Ye, Enxiao Li, Jun Zhang, Baorui Liu, Rongbo Lin, Aiping Zhou, Zhenyang Liu, Huiting Xu, Qiong Wang, Zuoxing Niu, Ying Yuan, Yanru Qin, Xiujuan Qu, Yuxian Bai, Ning Liu, Hailong Liu, Chunmei Bai, Yueyin Pan, Shubin Wang, Tao Wu, Qinghua Pan, Diansheng Zhong, Hongxia Lu, Junye Wang, Zhiyu Wang, Ting Deng, Hongfeng Gou, Xiwen Huang, Puhan Lu, Jie Yu, qian Xu, Linfang Wang, Yongxin Ren, Songhua Fan, Lin Shen, Mengyang Hong
| Nature Verified
Abstract MET proto-oncogene amplification (METamp) is associated with poor prognosis in gastric or gastroesophageal junction (G/GEJ) cancer. Currently, effective targeted therapies for G/GEJ cancer harboring METamp remain unavailable, and clinical evidence supporting the use of MET inhibitors in this disease population is limited. Here we report the results of a phase 2 study of savolitinib, an oral MET inhibitor, in patients with METamp G/GEJ cancer.
Open in Who Shared Issue with article?
See all 12 licensed articles (13 Total)